NCT06518837 - Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 30, 2024

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions

Hormone Receptor-Positive Breast CancerHER2-Negative Breast Cancer

Interventions

DRUG

Tirzepatide

The intervention aims to assess the feasibility, safety, and efficacy of tirzepatide for weight loss in patients with early-stage hormone receptor-positive, HER2-negative breast cancer, potentially improving treatment outcomes and overall health.

Trial Locations (7)

07202

NOT_YET_RECRUITING

Trinitas Comprehensive Cancer Center, Elizabeth

08690

NOT_YET_RECRUITING

RWJ Barnabas Health - Robert Wood Johnson University Hospital, Hamilton, Hamilton

07039

NOT_YET_RECRUITING

RWJBarnabas Health - Cooperman Barnabas, Livingston, Livingston

07740

NOT_YET_RECRUITING

RWJBarnabas Health - Monmouth Medical Center, Long Branch

08901

RECRUITING

Rutgers Cancer Institute, New Brunswick

07112

NOT_YET_RECRUITING

RWJBarnabas Health - Newark Beth Israel Medical Center, Newark

08876

NOT_YET_RECRUITING

RWJ Barnabas Health - Robert Wood Johnson University Hospital, Somerset, Somerville